CHICAGO, March 14, 2022 -- PRNewswire -- SIWA Therapeutics, Inc. (“SIWA”), a Chicago-based biopharmaceutical company announced today that SIWA’s proprietary humanized monoclonal antibody, SIWA318H, is efficacious in an immune competent humanized mouse xenograft model for pancreatic cancer. The study was conducted by the Translational Genomics research Institute (“TGEN”), pursuant to a SIWA-sponsored research agreement. Results of the pancreatic cancer study in humanized mice treated with SIWA318H included: Both the SIWA318H high dose and low dose treatment groups showed significant anti-tumor activity in a PSN1 human pancreatic cancer mouse xenograft tumor model by significantly reducing tumor growth (P-Value < 0.0001); There was a significantly higher number of complete remission cases in the treated groups compared to the isotype-treated control group. 37.5% (6 out of 16 mice) treated with SIWA318H high dose had…
SIWA CEO and Chief Scientific Officer, Lewis Gruber, was featured in a recent interview with Supertrends where he discussed how SIWA 318H targets cancerous, senescent, and virally infected cells. Read the full interview here: https://www.supertrends.com/senolytics-showcase-link-between-life-extension-and-therapeutics/
Read more here: https://www.biospace.com/article/siwa-therapeutics-grows-leadership-team-with-appointment-of-gabriela-rossi-ph-d-/
"While SIWA’s focus remains on developing a powerful therapeutic for aggressive cancers, the Covid-19 pandemic presented us with an opportunity to explore how 318H could also be used to treat infectious diseases." In this interview, our CEO and Chief Scientific Officer, Lewis Gruber, discusses the results of our recent preclinical tests, which confirmed 318H shows promise to become both a comprehensive cancer therapy and a broad-spectrum antiviral drug. Read the full interview here: https://startup.info/lewis-gruber-siwa-therapeutics/
Biospace.com has posted an article detailing our efforts to combat COVID-19. Read more here: https://www.biospace.com/article/chicago-biotech-company-testing-its-monoclonal-antibody-to-treat-covid-19/
We are pleased to announce that Lewis Gruber was recently named to the Aging Analytics Agency’s list of 1000 Longevity Leaders recognized in the research and academia sector for his work with SIWA Therapeutics. Aging Analytics is the longest-running and most comprehensive interactive platform of longevity professionals. The agency profiles public and private-sector influencers whose work in business, science, policy, philanthropy, or thought-leadership is instrumental in the longevity landscape.
SIWA Therapeutics is pleased to announce our participation in BIO Digital 2020, a virtual gathering of the global biotech industry. BIO is the world's largest trade association, which represents biotechnology companies, academic institutions, and other organizations on the forefront of innovation. This year, the BIO International Convention will transition into an entirely virtual event, providing even closer access to key partners via the BIO One-on-One Partnering. We look forward to our discussions at this year’s unique platform on June 8-12! If attending, please reach out to us firstname.lastname@example.org